- Home
- SVRN vs RNXT Comparison
SVRN vs RNXT Comparison
Compare SVRN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | RNXT |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 36.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SVRN | RNXT |
|---|---|---|
| Price | $1.26 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 162.0K | ★ 340.4K |
| Earning Date | 12-02-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,435,000.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.70 |
| 52 Week High | $79.25 | $1.69 |
Technical Indicators
Market Signals| Indicator | SVRN | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.46 |
| Support Level | N/A | $0.98 |
| Resistance Level | N/A | $1.25 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 60.87 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.